ANAHEIM, CA, April 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer of…
Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial HypertensionBOSTON and ATLANTA, April 03, 2024…
STOCKHOLM, SWEDEN / ACCESSWIRE / April 3, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical…
OKLAHOMA CITY, April 2, 2024 /PRNewswire/ -- In a momentous occasion, Oklahoma Proton Center, a leading provider of cutting-edge proton…
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system…
Previously served as Acting General Counsel to the Department of Veterans AffairsHOUSTON, TEXAS, April 02, 2024 (GLOBE NEWSWIRE) -- Nexalin…
Expect Topline Data for Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab for Alzheimer’s Disease in Q3 2024 Company raised $17.9 million…
TORONTO, ON / ACCESSWIRE / April 1, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…
Lead program, Berubicin, successfully passed pre-planned interim futility analysis milestone with recommendation from DSMB to proceed without modification in potentially…
Transitioned from Pre-Clinical to Clinical Stage company in FY 2023Phase 1/2a trial, designed to assess both healthy volunteers and patients…